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Abstract
Background: To describe the epidemiology and possible risk factors for the development of multidrug-resistant
tuberculosis (MDR-TB) in Namibia.
Methods: Using medical records and patient questionnaires, we conducted a case-control study among patients
diagnosed with TB between January 2007 and March 2009. Cases were defined as patients with
laboratory-confirmed MDR-TB; controls had laboratory-confirmed drug-susceptible TB or were being treated with
WHO Category I or Category II treatment regimens.
Results: We enrolled 117 MDR-TB cases and 251 TB controls, of which 100% and 2% were laboratory-confirmed,
respectively. Among cases, 97% (113/117) had been treated for TB before the current episode compared with 46%
(115/251) of controls (odds ratio [OR] 28.7, 95% confidence interval [CI] 10.3–80.5). Cases were significantly more
likely to have been previously hospitalized (OR 1.9, 95% CI 1.1–3.5) and to have had a household member with
MDR-TB (OR 5.1, 95% CI 2.1–12.5). These associations remained significant when separately controlled for being
currently hospitalized or HIV-infection.
Conclusions: MDR-TB was associated with previous treatment for TB, previous hospitalization, and having had a
household member with MDR-TB, suggesting that TB control practices have been inadequate. Strengthening basic
TB control practices, including expanding laboratory confirmation, directly observed therapy, and infection control,
are critical to the prevention of MDR-TB.
Background
Multidrug-resistant tuberculosis (MDR-TB) has become a
major public health problem and obstacle to global TB con-
trol [1,2]. MDR-TB is associated with higher case fatality
rates, especially among HIV-infected patients [3,4], and is
much more difficult and costly to treat than drug-
susceptible TB [5]. The worldwide burden of MDR-TB has
been growing, and in 2008, there were 440,000 estimated
new cases of MDR-TB, or 3.6% of all incident TB cases,
compared to 273,000 estimated new cases (3.2% of incident
TB cases) in 2000 [5-7]. However, these estimates may not
accurately represent the true global burden of MDR-TB as
they are based on surveillance reports from only 114
countries, of which only 10 are sub-Saharan countries with
recent or complete national data [5].
Despite the lack of comprehensive surveillance data
from Africa, MDR-TB has been recognized as an emer-
ging public health concern. In South Africa, clusters of
MDR-TB cases have been documented in institutional
and community settings and among HIV-infected
patients [3,8-12]. Epidemiologic investigations of these
and other outbreaks have demonstrated that previous
treatment for TB and transmission in institutional and
community settings are important risk factors in MDR-
TB development [10-15].
Since 2007, the National TB Control Program (NTCP)
in Namibia has documented an increase in drug-resistant
TB (DR-TB) [5,16]. However, there are few population-
level data available to evaluate the prevalence of MDR-TB
in Namibia. Namibia has one of the highest TB incidence
rates in the world, estimated at 665 new cases per 100,000
persons in 2008 [17]. Among incident TB cases, 59% are
estimated to be co-infected with HIV [17]. In 2008, 201
cases of MDR-TB were reported to the NTCP, and the
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estimated prevalence of MDR-TB was 3.8% among new
smear-positive TB cases and 16.5% among previously trea-
ted TB cases [17]. However, drug-susceptibility testing
(DST) is not routinely performed, making the reported
prevalence of MDR-TB in Namibia an underestimate of
the true burden.
Data about the relative contributions of specific risk
factors to the development of MDR-TB in Namibia are
also limited. In late 2008, an investigation of only 34
DR-TB patients by the NTCP and the U.S. Centers for
Disease Control and Prevention (CDC) found clinical
evidence suggesting acquired TB drug resistance related
to incomplete TB treatment in the community and
primary transmission of DR-TB in the hospital settings
(NTCP, unpublished data). In this report, we describe a
more extensive epidemiologic investigation of MDR-TB




This investigation was requested by Namibia's Ministry of
Health and Social Services (MOHSS) and was deemed to
be a response to an urgent public health problem. The
investigation consisted of two parts, data abstraction from
medical records and patient interviews. The data abstrac-
tion component of the investigation was determined to be
an outbreak response; CDC and the Namibian MOHSS do
not require human subjects consent for review of routine
medical records during outbreak investigations. The patient
interview portion of the investigation was conducted by
staff from the Namibian MOHSS. Patients' verbal informed
consent was obtained prior to the interview, but was not
required to be documented. The interviews were conducted
in the context of TB education and consent was obtained
while the interviewer determined which language the
patient felt most comfortable speaking. Medical records
data and patient interview data were linked by patient ID,
which was removed prior to analysis, which was done
anonymously.
Study design, site selection and participants
We conducted a case-control study among patients
diagnosed with TB between January 1, 2007 and March
31, 2009 in nine major cities in Namibia (Table 1). Study
participants were selected from inpatient and outpatient
departments of the main hospital providing TB services in
each city, and their respective local community-based
DOT clinics. These nine hospitals included seven of eight
NTCP-designated regional DR-TB treatment centers.
For our study, we defined cases as patients with a
laboratory-confirmed diagnosis of MDR-TB or extensively
drug-resistant TB (XDR-TB). MDR-TB was defined as a
Mycobacterium tuberculosis isolate with resistance to at
least isoniazid and rifampin. XDR-TB was defined as a
Mycobacterium tuberculosis isolate with resistance to iso-
niazid and rifampin, ofloxacin, and one of three injectable
second-line drugs [2].
We defined controls as patients if (1) they had
laboratory-confirmation of a TB isolate susceptible to
isoniazid, rifampin, ethambutol, and streptomycin (DST
not done on pyrazinamide); or (2) DST was not performed
but they were receiving Category I or Category II treat-
ment regimens in accordance with WHO and NTCP
guidelines [16,18,19].
NTCP TB treatment guidelines
In Namibia, TB culture and DST are reserved for TB
patients who have been previously treated or are suspected
of having DR-TB. Patients with confirmed MDR-TB are
required to receive inpatient treatment until sputum
culture conversion and can then complete their treatment
at an outpatient directly observed therapy (DOT) facility
[16,18,20]. Patients with presumed drug-susceptible TB
receive treatment through community-based outpatient
DOT clinics, unless complications require hospitalization.
At the time of this investigation, TB treatment regimens in
Namibia were based on 2003 WHO guidelines, defined as
follows: [18,19].
Category I – Initial phase of two months of isoniazid
(H), rifampin (R), pyrazinamide (Z), ethambutol (E) daily
followed by continuation phase of four months RH, for
new patients with any form of tuberculosis.
Category II – Initial phase of two months HRZE daily
and streptomycin (S) on weekdays, followed by one month
of HRZE daily, followed by continuation phase of five
months of RHE daily. To be used for relapse or return after
default of either Category I or Category II regimens, treat-
ment failure, or recurrent tuberculosis.
Category IV – Specially designed standardized or indivi-
dualized regimens for chronic (still sputum-positive after
supervised re-treatment); proven or suspected MDR-TB
patients.
Patient enrollment
Cases and controls were selected using convenience sam-
pling. For cases, we attempted to enroll all hospitalized
MDR-TB patients at the study hospitals and all MDR-TB
patients being treated on an outpatient basis if they came
to the hospital's outpatient clinic or the local DOT clinic
during our visit.
For controls, we attempted to enroll all patients who
met our study's definition of a control if they visited the
hospital outpatient clinic or local DOT clinic to receive
TB treatment on the days of our visit. We also selected
a convenience sample of hospitalized TB patients who
met our control definition.
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Data collection
Data were obtained through two different methods: 1) data
abstraction from medical records, and 2) patient interviews.
For the medical data, we abstracted data from TB treat-
ment cards, patient hospital and TB clinic charts, and
patient health passports (a small booklet containing a
person0s medical history) of cases and controls using a
modified data collection form from previous MDR-TB
investigations [21,22]. We collected basic demographic
information; information on previous and current TB
episodes; HIV infection and treatment; and TB-related
laboratory data. Study patients were classified as previously
treated for TB if there was evidence of treatment for a
previous TB episode in their medical record.
Table 1 Distribution of demographic and treatment characteristics of cases and controls
Cases (N = 117) Controls (N = 251) p valuea
n (%) or Mean (SD) n (%) or Mean (SD)
Education, years of schooling 7.5 (3.8) 7.4 (3.6) 0.87
Household size, number of people 6.3 (4.2) 5.8 (4.8) 0.31
Age (yrs.) <21 11 (9) 25 (10) 0.89
21-29 23 (20) 52 (21)
30-39 41 (35) 95 (38)
40-49 27 (23) 46 (18)
50-64 12 (10) 23 (9)
65+ 3 (3) 10 (4)
Male 65 (56) 139 (55) 0.93
Married/partnered 33 (28) 63 (25) 0.35
Born in Namibia 111 (95) 242 (96) 1.00
Treatment city Windhoek 36 (31) 79 (31) <.0001
Walvis Bay 23 (19) 28 (11)
Oshakati 23 (19) 49 (20)
Onandjokwe 7 (6) 26 (10)
Grootfontein 8 (7) 22 (9)
Rundu 7 (6) 10 (4)
Luderitz 6 (5) 10 (4)
Otijiwarongo 4 (4) 12 (5)
Keetmanshoop 3 (3) 15 (6)
Currently hospitalized 97 (83) 77 (31) <.0001
Current treatment regimen Category I 0 (0) 157 (63) <.0001
Category II 1 (1) 94 (37)
Category IV 116 (99) 0 (0)
Documented HIV testing 108 (92) 212 (84) 0.04
HIV- infectedb 55 (51) 141 (67) 0.007
Documented CD4 test resultc 24 (44) 56 (40) 0.76
Receiving ART c 32 (58) 59 (42) 0.04
Documented DST result ALL 117 (100) 4 (2) <.0001
MDR-TB 112 (96) 0 (0)
XDR-TBd 5 (4) 0 (0)
Previous TB treatment 113 (97) 115 (46) <.0001
Previous Category IV treatment 35 (30) 0 (0) <.0001
a p values are for known outcome values.
b among those with a documented HIV test.
c among those HIV-infected.
d defined as a Mycobacterium tuberculosis isolate with resistance to isoniazid and rifampin,
ofloxacin, and one of three injectable second-line drugs.
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MOHSS health care personnel interviewed cases and
controls in their local language, using a structured
questionnaire, to collect additional information about
socioeconomic status and possible risk factors for DR-
TB, such as information about previous episodes of
TB, adherence to DOT, and contact with TB and
MDR-TB patients. MOHSS shared the interview data
with the team conducting the medical data abstraction,
and the datasets were linked by the patient TB registry
number. The patient TB registry number was removed
from all electronic datasets once the linkage was com-
pleted and all hard copies of data abstraction and inter-
view forms were given to Namibia0s MOHHS for
safekeeping and storage.
Data management and data analysis
To detect significant differences in the distributions of
descriptive quantitative variables between cases and con-
trols, we used the chi-square statistic or Fisher's exact,
for cell size <=5, for dichotomous and categorical vari-
ables and t-tests for continuous and ordinal variables. A
two-sided univariate analysis was used to evaluate the
relationship between potential risk factors and MDR-TB.
For those variables significantly associated with MDR-
TB, at the level of p<0.05, an additional two-sided
univariate analysis was performed, controlling for those
descriptive variables that showed the most significant
difference, p<0.01, in distributions between cases and
controls. Two sub-analyses performed: one using only
Category I treatment controls and one using only
Category II treatment controls. All data were analyzed
using the statistical program SAS 9.1 (SAS Institute,
Cary, NC, USA). Statistical significance was considered
at an alpha of <0.05.
Results
Patient characteristics
We reviewed medical records of 368 patients, of whom
117 (32%) were MDR-TB cases and 251 (68%) were TB
controls. All 117 cases (100%) and 4 (2%) controls were
confirmed by DST. Having a DST performed was
significantly associated with previous treatment
(p<0.0001), reporting a household member with MDR-
TB (p=0.0004), and previous hospitalization (p=0.018).
Interviews were conducted with the 106 (91%) cases
and 244 (97%) controls available when study staff was
on-site. Demographic characteristics were similar
between cases and controls: mean age was roughly
36 years, approximately 55% were male, more than
90% were born in Namibia, and over 60% were treated
in one of three large cities (Table 1). Patient knowledge
about TB was limited: 75 (64%) cases and 167 (67%)
controls did not know that TB was spread through
person-to-person transmission (p =0.83).
MDR-TB cases were significantly more likely to have
been previously treated for TB, although previous treat-
ment was also common among controls, 113 (97%) and
115 (46%), respectively; p < 0.0001. Thirty-five (30%) cases
had been previously treated with a Category IV regimen.
Among those who were previously treated for TB, 77
(68%) of cases and 80 (70%) of controls had a TB treatment
outcome of default, failure, or unknown outcome for the
most recent previous TB treatment episode (p=0.82).
Documentation of HIV testing was high among both
cases and controls, at 108 (92%) and 212 (84%), respect-
ively (p = 0.04). Of those who were tested, 55 (51%) of
cases were HIV-infected compared to 141 (67%) of
controls (p = 0.007). Of those who were HIV-infected, 32
(58%) of cases and 59 (42%) of controls were on antire-
troviral therapy (ART) (p=0.04). Among HIV-infected
patients who were not yet on ART, 6/23 (26%) cases and
36/82 (44%) of controls could be considered for ART based
on their recorded CD4 count and clinical stage, according
to Namibian guidelines [18,23].
Possible risk factors associated with being an MDR-TB
case
In a univariate analysis, having a documented previous TB
episode was significantly associated with being an MDR-TB
case (odds ratio [OR] = 28.7, 95% confidence interval [CI]
10.3–80.5). Having had a household member with MDR-
TB (OR = 5.1, 95% CI 2.1–12.5), documentation of HIV
testing (OR = 2.2, 95% CI 1.0–4.7), previous hospitalization
(OR = 1.9, 95% CI 1.1–3.5), and receiving ART (OR = 2.3,
95% CI 1.1–4.6), were significantly associated with being a
case (Table 2). HIV infection was inversely associated with
being a case (OR = 0.5, 95% CI 0.3–0.9).
In a univariate analysis adjusting for current
hospitalization status, previous hospitalization and
documented HIV testing were no longer significantly
associated, while HIV infection remained negatively
associated with being an MDR-TB case (Table 3). The
crude odds ratios for all possible risk factors associated
with being an MDR-TB case, when adjusted for HIV
infection, remained significant (Table 3). A documen-
ted previous TB episode continued to be the strongest
possible risk factor for MDR-TB status (OR = 23.2, 95%
CI 8.4–64.4). In the sub-analyses comparing all MDR-
TB cases to the subset of controls receiving Category I
treatment, HIV infection no longer had a negative
association among the six unadjusted possible risk
factors associated with being an MDR-TB case
(Table 4). In comparing all MDR-TB cases to the subset
of controls receiving Category II treatment, HIV infec-
tion remained negatively associated and having had a
household member with MDR-TB remained positively
associated with being an MDR-TB case.
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Discussion
Detecting the emergence and controlling the spread of
MDR-TB begins with its timely diagnosis. However, only
3% of re-treatment controls had a documented DST,
despite NTCP0s recommendation that all re-treatment
patients receive DST. While recognizing limited resources
for DST and the high percentage of TB retreatment,
Namibia needs to improve diagnosis of DR TB. This will
necessitate impressing upon health care personnel the need
to comply with NTCP DST guidelines.
Compared to controls, we found MDR-TB cases were 28
times more likely to have been treated for a previous TB
episode, and that among those previously treated, the most
recent outcome was failure, default, or unknown for
Table 3 Association between selected characteristics and MDR-TB case, adjusted for current hospitalization status and
HIV infection
Adjusted for current Adjusted for
Crude association hospitalization status HIV infection
OR (95% CI) AOR (95% CI) AOR (95% CI)
Previous TB treatment (N=349) 28.7 (10.3 – 80.5) 13.5 (4.5 – 40.9) 23.2 (8.4 – 64.4)
Currently hospitalized (N=364) 12.8 (6.9 – 24.0) n/a n/a 11.5 (6.3 – 21.3)
Previously hospitalized, any reason (N=199) 1.9 (1.1 – 3.5) 1.3 a (0.6 – 2.7) 1.9 (1.0 – 3.5)
Household MDR-TB contact (N=236) 5.1 (2.1 – 12.5) 3.8 (1.3 – 10.8) 5.3 (2.0 – 13.8)
Documented HIV testing (N=368) 2.2 (1.0 – 4.7) 1.4 a (0.6 – 3.7) n/a n/a
HIV infection (N=320), pos. vs. neg. 0.5 (0.3 – 0.9) 0.5 (0.3 – 0.8) n/a n/a
Receiving ART (N=169) 2.3 (1.1 – 4.6) 2.7 (1.2 – 6.0) 2.3 (1.1 – 4.6)
a ORs are no longer statistically significant when adjusted, p> 0.05.
Table 2 Association between independent demographic and clinical characteristics and MDR-TB case
Casesa Controlsa OR (95% CI)
n (%) n (%)
Type of housing Mud 13 (12) 7 (3) 4.6 (1.8 – 11.9)
All other types 94 (88) 234 (97) 1.0
Previous TB treatment Yes 113 (97) 115 (50) 28.7 (10.3 – 80.5)
No 4 (3) 117 (50) 1.0
Site of TB b Pulmonary 115 (98) 183 (93) 4.4 (0.9 – 19.7) c
With extra-pulmonary 2 (2) 14 (7) 1.0
Currently hospitalized Yes 97 (85) 77 (31) 12.8 (6.9 – 24.0)
No 17 (15) 173 (69) 1.0
Previously hospitalized b, d Yes 71 (70) 54 (55) 1.9 (1.1 – 3.5)
No 30 (30) 44 (45) 1.0
Household TB contact Yes 64 (62) 130 (55) 1.4 (0.8 – 2.2)
No 39 (38) 108 (45) 1.0
Household MDR-TB contact b Yes 16 (21) 8 (5) 5.1 (2.1 – 12.5)
No 60 (79) 152 (95) 1.0
Household respiratory deathe Yes 32 (31) 57 (24) 1.4 (0.8 – 2.3)
No 71 (69) 176 (76) 1.0
Documented HIV testing Yes 108 (92) 212 (84) 2.2 (1.0 – 4.7)
No 9 (8) 39 (16) 1.0
HIV infection b Positive 55 (51) 141 (67) 0.5 (0.3 – 0.9)
Negative 53 (49) 71 (33) 1.0
a Different denominators due to ″unknown″ and missing data.
b =>10% of responses ″unknown″ or missing data.
c Fisher0s exact test p=0.036.
d Previously hospitalized for any reason.
e Household member death from TB/respiratory illness.
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roughly 70% of both cases and control. The association
between previous TB treatment and MDR-TB has been
noted in investigations in other countries [13-15,24,25],
while more recent studies have observed that it is previous
treatment failure that is significantly associated with MDR-
TB [3,25] Our findings underscore the need to improve
basic TB control practices to ensure that all TB patients
adhere to and complete TB treatment. TB has been recog-
nized as a significant public health problem in Namibia
since its independence in 1990 and the NTCP has contin-
ually revised its TB control guidelines, in order incorporate
updated WHO recommendations and address DR-TB
[16,18,19,26]. However, considerable difficulties exist in
providing adequate DOT in a vast but sparsely populated
country with high TB prevalence and shortages of trained
health care workers [17]. As in other sub-Sahara African
countries, the NTCP has introduced community DOT
treatment, so that patients in remote areas can easily access
DOT [27-29]. These and other interventions need to be
strengthened to improve basic DOT coverage and prevent
continued emergence of drug-resistant strains in Namibia.
Evidence of transmission of MDR-TB within households
and in the community in the current study is not surprising
and has also been documented in neighboring South Africa
[11,12]. In our investigation, nearly two-thirds of patients
being treated for TB were unaware of how TB is spread,
making it unlikely that these patients or their families were
aware of measures that could prevent the spread of TB.
These findings suggest a need for increased TB education
for cases and their household members. In the current
study, MDR-TB cases were almost twice as likely to have
been previously hospitalized, and nosocomial spread of
MDR-TB and institutional outbreaks of XDR-TB have been
well-documented in sub-Saharan Africa and elsewhere
[10,13,30]. Although Namibia developed new infection con-
trol guidelines in 2008 and WHO recently revised its policy
on TB infection [20,31], TB infection control measures have
not been widely implemented in most Namibian facilities.
It is essential for countries such as Namibia to implement
effective infection control practices, especially in institu-
tional settings.
Like many countries in sub-Saharan Africa, Namibia
has experienced an increase in TB incidence, from 322
per 100,000 persons in 1990 to a peak of 817 per
100,000 persons in 2004, largely related to the growing
HIV epidemic. There is conflicting evidence as to
whether HIV is an independent risk factor for DR-TB
[24,25,32,33]. In our investigation, we found that HIV
infection was negatively associated with MDR-TB, i.e.
HIV infection was ″protective″ against MDR-TB. As
suggested by other studies, this may have been due to
HIV- infected persons dying at a higher rate than HIV-
uninfected person, such that HIV-infected persons were
less likely to live to the point of either developing MDR-
TB, or to die before being diagnosed with MDR-TB. The
higher death rate among HIV- infected persons is
possibly caused by the combination of 1) poor treatment
outcomes, due to malabsoprtion of anti-TB drugs or
lower rates of adherence, and 2) a greater likelihood of
being exposed to MDR-TB patients during medical visits
or hospitalizations [3,34-39]. With CD4 count informa-
tion documented for less than half of HIV-infected cases
and controls, improved linkages to HIV care and treat-
ment services and earlier initiation of ART are critical.
WHO recently revised its treatment recommendations
for HIV-infected TB patients to initiate ART earlier,
regardless of CD4 count, and this may be especially
important for HIV-infected patients with MDR-TB [40].
Although our investigation showed associations
between various characteristics and MDR-TB, assessing
these as risk factors is constrained by the limitations of
our investigation. First, because of Namibia's resource
limitation and the urgent nature of our investigation,
DST was performed almost exclusively (96%) on retreat-
ment patients, making retreatment necessary for obtai-
ning an MDR-TB diagnosis. Thus, it was not possible to
fully assess the extent of primary MDR-TB transmission
and the lack of previous treatment outcome data did not
allow us to assess this effect. Second, few controls had a
documented DST result, potentially leading to misclassi-
fication bias. Generally, this type of misclassification
would bias the associations towards the null, suggesting
Table 4 Association between selected characteristics and MDR-TB case, using two different control subgroups
Using only Category I Using only Category II
Crude Association Controls (N=157) Controls (N=94)
OR (95% CI) OR (95% CI) AOR (95% CI)
Previous TB episode 28.7 (10.3 – 80.5) 110.9 (37.7– 326.8) 2.3 a (0.6 – 8.0)
Previously hospitalized, any reason 1.9 (1.1 – 3.5) 3.4 (1.7 – 6.7) 0.8 a (0.4 –1.9)
Household MDR-TB contact 5.1 (2.1 – 12.5) 6.1 (1.9 – 19.2) 4.0 (1.3 – 12.7)
Documented HIV testing 2.2 (1.0 – 4.7) 2.4 (1.1 – 5.3) 1.9 a (0.8 – 4.7)
HIV infection, pos. vs. neg. 0.5 (0.3 – 0.9) 0.6 a (0.4 – 1.1) 0.4 (0.2 – 0.7)
Receiving ART 2.3 (1.1 – 4.6) 2.8 (1.3 – 6.1) 1.7 a (0.7 – 3.8)
a ORs are not statistically significant, p< 0.05.
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that the associations reported in this investigation are
true associations. However, as the major associations
were also associated with having a DST, the effect of this
misclassification might have a more complex effect. We
performed two sub-analyses that restricted the control
groups to either CAT I, of which 28/142 (20%) were
previous treated for TB or CAT II, of which 87/94 (93%)
were previously treated. These analyses suggest that
CAT II controls may have been more likely to be mis-
classified as compared to CAT I controls, for which 5 of
the 6 crude associations remained significant. Third,
because NTCP guidelines recommend inpatient treat-
ment for patients with DR-TB but not drug-susceptible
TB, patients selected from inpatient facilities were more
likely to be MDR-TB cases. Documentation was more
extensive for inpatients, which could have resulted in an in-
formation bias for MDR-TB cases. Although hospitalization
status confounds the magnitude of the crude associations,
it does not change their significance or direction. Lastly, we
were unable to fully assess the temporality of contact with
patients with TB or MDR-TB and our study cannot defini-
tively establish nosocomial or household transmission.
Additional investigations in Namibia are needed to
adequately describe the amount of primary and acquired
MDR-TB.
Conclusion
In summary, we found that previous TB treatment, previ-
ous hospitalization, and household contact with an MDR-
TB case were associated with MDR-TB in Namibia. Our
findings reinforce the importance of maintaining strong
overall TB control measures, to ensure adherence to diag-
nostic protocols, that all TB patients complete an appropri-
ate treatment regimen through DOT programs, and that
appropriate household and institutional infection control
measures are observed. This has become even more critical,
in light of the high prevalence of HIV-infection in Namibia,
which may decrease adherence and/or the effectiveness of
TB treatment and increase the risk of exposure to MDR-
TB due to HIV-related hospitalizations. Finally, enhancing
patient education is critical in helping patients and their
families understand the importance of treatment adherence
and implementing measures to prevent the spread of TB
within the household and the community.
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